Profil Penderita Tumor Ganas Sinonasal di RSUP H. Adam Malik Medan Tahun 2005-2009

Abstract

Background. Nasal and paranasal sinus tumors also called sinonasal tumors are rare, whether benign or malignant. Most of this malignancies are growing from the maxillary sinus. In Indonesia and worldwide get only about 1% of malignancies throughout the body and 3% of malignancies in the head and neck. Exposure to substances such as wood dust, textile or leather dusts, nickel, isopropyl oils, among others, has been implicated as a predisposing factor to sinonasal malignancies. The symptoms depend on the site and extent of tumor involvement. Nasal symptoms of unilateral nasal obstruction, rinorea, mixed with blood or secretions occurred epistaxis. Signs and symptoms are often ignored by patients and often difficult to distinguish from benign lesions and inflammatory disorder, and only treated with common antibiotics, that tend to diagnosed at advanced stage. Ancillary examinations such as CT scans, MRI, positron emission tomography (PET) and angiography are helpful in differential diagnosis, whereas histopathologic examination is the definitive diagnosis. Sinonasal malignancy is a cause of otorhinolaryngologic morbidity and mortality in worldwide. With an accurate profile sinonasal malignancy, we can make anpearlypdetectionpandptreatment. The purpose of this research is to get data about patient’s profile of sinonasal malignancy at H. Adam Malik General Hospital Medan on 2005-2009. Methods. This research was designed a descriptive research, explaining data was getting from patient of sinonasal malignancy’s medical record was done CT scan and histopathological examination on Januari 2005 until December 2009 from H. Adam Malik in Medan. Results. The result of this research shows that patient of sinonasal malignancy mostly found on male (58,8%), age group is 41-50 (35,2%), the main complain is nasal obstruction (56,9%), tumor location is nasal cavuty and paranasal sinus (60,8%) histological type is non keratinizing squamous cell carcinoma (56,9%) and on patient with clinical stage is IV (56,9%).